Targeting multiple ABC transporters may be more prospective given that co‐expression of different ABC transporters is common in tumor tissues and multitargeting drugs may be beneficial to avoid compensatory upregulation of another transporter induced by selective inhibition of a single transporter.133. The gene discussed is ABCG2; the disease is neoplasm.